本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本次计提减值准备情况概述 根据《企业会计准则》及天津久日新材料股份有限公司（以下简称公司）会 计政策、会计估计的相关规定，为真实、准确地反映公司截至 2025 年 9 月 30 日 的财务状况及经营成果，本着谨慎性原则，公司对截至 2025 年 9 月 30 日公司及 子公司的应收账款、其他应收款、长期应收款、存货等资产进行了减值测试，2025 年前三季度确认的各项资产减值损失合计为 1,592.24 万元，具体情况如下： 单位：万元 | 资产名称 | 2025 年前三季度计提减值损失金额 | | --- | --- | | 坏账损失 | -176.12 | | 存货跌价损失 | -1,416.12 | | 合计 | -1,592.24 | 证券代码：688199 证券简称：久日新材 公告编号：2025-062 天津久日新材料股份有限公司 关于 2025 年前三季度计提资产减值准备的公告 在正常生产经营过程中，以该存货的估计售价减去估计的销售费用和相关税费后 的金额，确定 ...

Group 1 - The company, Jiu Ri New Materials, announced a provision for impairment losses totaling 15.92 million yuan, impacting the total profit by the same amount for the first three quarters of 2025 [1] - The revenue composition for Jiu Ri New Materials in 2024 is as follows: 78.4% from light-curing materials, 21.29% from fine chemicals, 0.18% from electronic chemicals, and 0.13% from other businesses [1] - As of the report, the market capitalization of Jiu Ri New Materials is 4 billion yuan [1] Group 2 - The Chinese innovative drug sector has generated 80 billion USD in overseas licensing deals this year, indicating a robust secondary market for biopharmaceuticals [1] - There is a contrast between the hot secondary market and the cooling fundraising environment in the primary market for biopharmaceuticals [1]

审议通过《关于公司 2025 年第三季度报告的议案》 经与会监事审议，公司监事会认为：公司 2025 年第三季度报告的编制和审 议程序符合法律、法规、《公司章程》和公司内部管理制度的各项规定；报告的 内容和格式符合上海证券交易所的各项规定，所包含的信息能真实、准确、完整 地从各个方面反映公司 2025 年第三季度实际情况，不存在任何虚假记载、误导 性陈述或者重大遗漏；未发现参与公司 2025 年第三季度报告编制和审议的人员 有违反保密规定及损害公司利益的行为。公司监事会同意公司《2025 年第三季 度报告》。 证券代码：688199 证券简称：久日新材 公告编号：2025-061 天津久日新材料股份有限公司 第五届监事会第二十七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 天津久日新材料股份有限公司（以下简称公司）第五届监事会第二十七次会 议（以下简称本次会议）于 2025 年 10 月 24 日在公司会议室以现场方式召开， 本次会议通知已于 2025 年 10 月 18 日以专人 ...

Financial Performance - The company's operating revenue for the third quarter reached ¥383,678,956.75, representing a year-on-year increase of 7.79%[4] - The total profit for the period was ¥12,469,505.02, while the net profit attributable to shareholders was ¥11,777,137.36[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥2,854,496.27, showing a significant recovery compared to a loss of ¥7,314,155.73 in the previous year[4] - The basic and diluted earnings per share for the quarter were both ¥0.07, compared to ¥0.02 for the same period last year[4] - The weighted average return on equity for the quarter was 0.46%, up from 0.11% year-to-date[4] - Total operating revenue for the first three quarters of 2025 was CNY 1,097,176,424.21, a decrease of 2.6% compared to CNY 1,124,063,386.66 in the same period of 2024[18] - Net profit for the first three quarters of 2025 was a loss of CNY 4,931,390.65, an improvement compared to a loss of CNY 27,382,715.42 in the same period of 2024[20] - Basic earnings per share for the first three quarters of 2025 were CNY 0.02, compared to a loss of CNY 0.15 in the same period of 2024[21] - The company reported a total comprehensive income of CNY 516,447.45 for the first three quarters of 2025, a significant improvement from a loss of CNY 32,904,544.79 in 2024[21] Cash Flow and Management - The cash flow from operating activities showed a net outflow of ¥19,948,382.46 year-to-date, indicating challenges in cash management despite revenue growth[4] - The company reported a net cash inflow from operating activities of CNY 883,124,334.62 for the first three quarters of 2025, compared to CNY 935,845,918.78 in 2024, reflecting a decrease of 5.6%[23] - Cash inflow from operating activities decreased to ¥687.95 million from ¥761.47 million, a decline of approximately 9.6% year-over-year[24] - Net cash outflow from operating activities was ¥19.95 million, slightly improved from ¥21.74 million in the previous period[24] - Cash inflow from investment activities totaled ¥1.17 billion, down from ¥1.20 billion, reflecting a decrease of about 1.0%[24] - Net cash outflow from investment activities was ¥61.45 million, an improvement from ¥150.44 million in the prior period[24] - Cash inflow from financing activities increased to ¥821.07 million from ¥737.35 million, representing an increase of approximately 11.3%[24] - Net cash outflow for financing activities was ¥643.50 million, compared to ¥532.85 million previously, indicating a rise of about 20.8%[24] - The ending cash and cash equivalents balance rose to ¥639.74 million from ¥579.09 million, an increase of approximately 10.5%[25] - The company reported a net increase in cash and cash equivalents of ¥98.65 million, compared to ¥36.99 million in the previous period[24] Assets and Liabilities - The company's total assets increased by 4.97% to ¥4,210,550,065.51 compared to the end of the previous year[5] - The company's total current assets as of September 30, 2025, amount to ¥1,786,749,621.18, an increase from ¥1,642,058,832.97 as of December 31, 2024[16] - Total assets as of September 30, 2025, are ¥4,210,550,065.51, up from ¥4,011,278,629.43[17] - Current liabilities increased to ¥1,247,494,026.63 from ¥1,057,395,234.02, showing a rise of approximately 18%[17] - The total liabilities increased to CNY 1,515,197,760.63 in 2025 from CNY 1,353,075,636.87 in 2024, marking an increase of 12%[19] - The total equity attributable to shareholders of the parent company was CNY 2,567,282,106.18, slightly up from CNY 2,556,781,731.64 in 2024[19] Research and Development - Research and development expenses totaled ¥18,274,406.87, accounting for 4.76% of operating revenue, a decrease of 1.09 percentage points from the previous year[5] - Research and development expenses for the first three quarters of 2025 were CNY 54,774,529.44, a decrease of 9.1% from CNY 60,481,355.82 in 2024[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 12,448[13] - The largest shareholder, Zhao Guofeng, holds 29,459,697 shares, representing 18.27% of total shares[13] Non-Recurring Gains - Non-recurring gains for the period amounted to ¥8,922,641.09, contributing positively to the overall profit[8] Strategic Focus - The company has focused on deepening cooperation with existing customers and expanding its customer base, which has positively impacted profitability[9] Future Considerations - The company plans to implement new accounting standards starting in 2025, which may affect future financial reporting[26]

Fundraising Overview - The company successfully raised a total of RMB 185,415.74 million by issuing 27,806,800 shares at a price of RMB 66.68 per share, with a net amount of RMB 170,929.30 million after deducting issuance costs of RMB 14,486.45 million [1] Changes in Fundraising Projects - The company decided to reallocate RMB 48 million of unused fundraising to two new projects: a 1,500-ton acyl phosphine oxide series photoinitiator project and a 350-ton hydroxy ketone series photoinitiator project, with the approval from the board and shareholders [2][3] Fund Management and Supervision - The company established special fundraising accounts for the new projects and signed a tripartite supervision agreement with the banks and the sponsor to ensure compliance with fundraising management regulations [3][4] - The special accounts are designated solely for the respective projects, ensuring that funds are not used for other purposes [5][9] Agreement Details - The tripartite agreement outlines the responsibilities of each party, including the management of funds, supervision by the sponsor, and the requirement for monthly account statements [6][7] - The agreement will remain effective until all funds are utilized and the supervision period concludes [8][12]

Group 1 - The company Tianjin Jiuri New Materials Co., Ltd. has signed a tripartite supervision agreement for the management of raised funds [1][4] - The company raised a total of RMB 185,415.74 million by issuing 27,806,800 shares at a price of RMB 66.68 per share, with a net amount of RMB 170,929.30 million after deducting issuance costs [2][3] - The company has allocated RMB 48 million of unused raised funds to two new projects: a 1,500-ton acyl phosphine oxide series photoinitiator project and a 350-ton hydroxy ketone series photoinitiator project [3][4] Group 2 - The tripartite supervision agreement was signed on October 17, 2025, involving Tianjin Jiuri, its wholly-owned subsidiary Inner Mongolia Jiuri New Materials Co., Ltd., and the sponsor and bank [4][6] - The agreement stipulates that the funds must be stored in a special account solely for the designated projects and cannot be used for other purposes [6][10] - The sponsor has the right to supervise the use of the raised funds and must conduct semi-annual inspections of the fund management [7][11]

证券代码：688199 证券简称：久日新材 公告编号：2025-060 天津久日新材料股份有限公司 关于签署募集资金三方监管协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意天津久日新材料股份有限公司首次公 开发行股票注册的批复》（证监许可[2019]1887 号），同意公司首次公开发行 股票的注册申请，公司向社会公开发行人民币普通股 2,780.68 万股，每股面值 人民币 1.00 元，每股发行价为人民币 66.68 元，共募集资金人民币 185,415.74 万元，扣除发行费用 14,486.45 万元（不含税），实际募集资金净额为人民币 170,929.30 万元。前述募集资金到位情况经大华会计师事务所（特殊普通合伙） 验证，并出具了《天津久日新材料股份有限公司发行人民币普通股（A 股） 2,780.68 万股后实收股本的验资报告》（大华验字[2019]000423 号）。公司已 对募集资金进行了专户存储，并与保荐机构、存放募集资金的商业银行签署了募 ...

格隆汇10月17日丨久日新材(688199.SH)在投资者互动平台表示，今年第三季度，公司光敏剂销量较去 年同期显著提升，目前光敏剂已形成规模化销售。 ...

Core Points - Jiu Ri New Materials experienced a stock price decline of 2.03% on October 17, trading at 23.64 CNY per share with a market capitalization of 3.811 billion CNY [1] - The company has seen a year-to-date stock price increase of 57.08%, but has faced a decline of 14.04% over the last five trading days [1] - The company specializes in photoinitiators, with 79.50% of its revenue coming from this segment [1][2] Financial Performance - For the first half of 2025, Jiu Ri New Materials reported a revenue of 713 million CNY, a year-on-year decrease of 7.11%, while the net profit attributable to shareholders was -9.0573 million CNY, an increase of 29.69% [2] - The company has distributed a total of 203 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [2] Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 3.44% to 10,900, with an average of 14,767 circulating shares per shareholder, an increase of 3.56% [2] - New institutional shareholders include Penghua Quality Governance Mixed Fund, holding 2.1373 million shares, and several others, indicating increased institutional interest [2]

证券代码：688199 证券简称：久日新材 公告编号：2025-059 天津久日新材料股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 10 月 20 日（星期一）至 10 月 24 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （jiuri@jiuri.com.cn）进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 天津久日新材料股份有限公司（以下简称公司）将于 2025 年 10 月 25 日发布 公司《2025 年第三季度报告》，为便于广大投资者更全面深入地了解公司 2025 年 第三季度的经营成果、财务状况，公司计划于 2025 年 10 月 27 日（星期一） 10:00-11:00 召开 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 董事、总裁：解敏雨先生 董事、副总裁（研发负责人）：张齐先生 一、说明会类型 本次业绩说明会以网络互动形式召开 ...